Source comparison
Growth Hormone Secretagogues: Pulsatile vs Sustained Release Dynamics
GHRP-2 (Growth Hormone Releasing Peptide-2) and GHRP-6 both act as ghrelin receptor agonists, triggering rapid GH release from the anterior pituitary within 15–30 minutes of subcutaneous administration. Peak plasma GH occurs at 30–45 minutes, followed by hepat
This comparison does not assign a generated winner or score.
- GHRP-2 (Growth Hormone Releasing Peptide-2) and GHRP-6 both act as ghrelin receptor agonists, triggering rapid GH release from the anterior pituitary within 15–30 minutes of subcutaneous administration. Peak plasma GH occurs at 30–45 minutes, followed by hepatic IGF-1 synthesis with measurable elevation at 60–90 minutes post-injection. The IGF-1 response is dose-dependent: studies using 100 mcg GHRP-2 showed mean IGF-1 increase of 1.5× baseline, while 300 mcg doses produced 2.0–2.2× baseline elevation. The biological relevance is that pulsatile protocols (dosing 2–3 times daily) more closely mimic endogenous GH secretion patterns than sustained elevation, which may matter for receptor sensitivity and downstream signaling pathway activation.
- CJC-1295 without DAC (Drug Affinity Complex) produces GH pulses lasting 30–60 minutes, similar to GHRP compounds. CJC-1295 with DAC extends the half-life to 6–8 days through albumin binding, sustaining GH and IGF-1 elevation across the entire dosing interval. A single 2 mg subcutaneous injection of CJC-1295 DAC produces IGF-1 elevation of 1.3–1.8× baseline for 7–10 days in adult subjects, as demonstrated in Phase I clinical trials published in Drug Metabolism and Disposition. The trade-off: researchers lose control over precise timing and cannot rapidly terminate the effect if adverse events occur. The peptide remains active until hepatic clearance completes.
- MK-677 (ibutamoren) is a non-peptide ghrelin mimetic with oral bioavailability and a 24-hour half-life. At 25 mg daily, it produces sustained IGF-1 elevation of 60–90% above baseline with stable plasma concentrations after 7–10 days of dosing. Unlike injectable peptides, MK-677 doesn't require reconstitution or refrigeration, simplifying protocol compliance in longitudinal studies. Research published in the Journal of Gerontology found that 12 months of daily MK-677 administration maintained IGF-1 levels at 160–180% of baseline without tachyphylaxis. Receptor downregulation did not occur at therapeutic doses. The primary limitation is appetite stimulation through ghrelin receptor activation, which confounds metabolic and body composition endpoints in studies where caloric intake isn't controlled.